News

Jordana Holovach (09.8.2023) 2 min
(Canavan Disease)

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In tincidunt enim nec turpis laoreet, et eleifend lacus malesuada. Fusce convallis faucibus leo in fringilla. Mauris ut consectetur est. Praesent tincidunt semper porttitor. Pellentesque vestibulum, ex in viverra faucibus, erat orci vulputate arcu, ut fermentum ante nisl vitae elit. Nunc ornare diam sit amet commodo bibendum. Aliquam id ultricies diam. Mauris in tempus velit. Integer imperdiet neque in lobortis aliquet. Donec tincidunt, felis non posuere lobortis, augue nisl commodo augue, at convallis felis ante et sapien.

Jordana Holovach (09.8.2023) 2 min
(Canavan Disease)

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Jordana Holovach (09.8.2023) 2 min
(H-ABC)

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Jordana Holovach (09.8.2023) 2 min
(Canavan Disease)

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Jordana Holovach (09.8.2023) 2 min
(Canavan Disease)

Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency

Wakefield, Mass., April 25th, 2023- Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovative Licensing and Access Pathway (ILAP) designation to the…

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Phasellus cursus sapien mi, posuere sagittis velit suscipit et in commodo porttitor felis, at tincidunt nibh sodales quis Pellentesque scelerisque, sem eu laoreet sodales, elit leo dignissim felis, at hendrerit tellus augue sit amet dolor

Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency

Join Our Community